First Berlin Equity Research GmbH’s Post

Epoch 9: What Downturn? Europe's VC Market Defies Gravity 👉Disciplined European valuations appear attractive 👉RIF Analysis - voluntary vs. involuntary 👉VC $$$'s starting to flow again? 👉Top Biotech Investor Rankings https://lnkd.in/dEkBy2bY

2023 ended on a high note for biotech, with positive signs like the XBI rebounding over 30% from its lows and potential rate cuts on the horizon for 2024. Is the improved sentiment sustainable? Late last year, ENTENTE CEO Virginia Amann spoke with industry veterans Gabriel Cavazos, Marian Nakada, Ph.D., Dennis Purcell and Brad Sitko at a salon hosted by Demy-Colton find out.   The discussion revolves around the challenges faced by biotech CEOs in a slow IPO market, exploring various financing strategies and the importance of strategic planning.    Read the full story in ENMEDIA, part of our JPM Week series. Link in comments.   #biotech #finance #venturecapital #innovation #jpmhc24

Company delivered monthly 'management reports' to investors for 74 consecutive months, leading to October listing - [Interview] Keum Changwon, CEO of 3billion - "Even covered employees' salaries out of pocket as investment cliff loomed" - "Following guidance from Lee Jungkue, CEO of Bridge Bio, I provided monthly summaries of key company situations to investors" - "Our transparency in management prevented investor questions at the general shareholders' meeting, enabling us to successfully attract investment up to the pre-IPO stage" - Preliminary examination requested in April, completed in 3 months: KOSDAQ technology special listing achieved in October - "Overseas sales now exceed 70-75%, with the gap to domestic sales widening" - Plans to launch a genetic testing lab with a U.S. branch next year: On-site sample collection and base sequence analysis https://lnkd.in/gmiWEEAD

#News #JPM24: Several experts on a panel Wednesday at #JPM’s Biotech Showcase expressed positive attitudes for the coming year on the investment side, with Andrew Lam, PharmD, the principal of special investments at Ally Bridge Group, commenting that the panel’s title should be “Biotech in 2024: Let the good times roll.” In all seriousness, Lam noted that there are “signs of life” in the industry. Gabriel Cavazos a senior managing director of investment banking at Leerink Partners, said that while the industry has been through a lot over the last two years, he is ready to see more of a rally in the market. “What’s exciting is despite the hard times in 2023 . . . the last two months of the year have been quite productive, November and December,” noted panelist Maha Katabi, PhD, CFA, general partner at Sofinnova Investments . “We closed the year with 23 M&A deals in the industry. . . . And the last time we exceeded that number was . . . in 2002.” On the #IPO front, Lam noted that more companies could go public as soon as next week and expressed cautious optimism about the prices. This will give investors even more confidence as more capital is being “infused” into the sector. While Lam did say valuations are being compressed and raises are shrinking in deal size compared to previous years, the market is getting better, and sizes are bound to increase. In Cavazos’s view, the IPO front is only just returning to an “equilibrium” stage. Read from from Tyler Patchen and BioSpace using the link in the comments below.

‘Next Wave of IPOs’ Will Arrive in Summer, Predicts Biotech-Focused VC Partner Delegates at the LSX World Conference in London seemed to agree on one thing—the biotech IPO window finally re-opened this year. This sentiment has persisted despite the fact that the initial run of public offerings died down by the spring. For Francesco De Rubertis, co-founder and partner of London-based life sciences investment firm Medicxi, the current lull is to be expected. What’s more, he expects “at least a number of IPOs” to arrive as soon as the summer. “In the absence of other external [factors], the natural dynamics of markets should say that now there will be another big number of investors that will become active on the public markets, and that will translate in the next wave of IPOs,” he told Fierce in an interview on the sidelines of the LSX conference. https://lnkd.in/d6ZB_eF3 #aspenalert #biotech #bioprocess

Drop me a message if you want to grab a coffee and find out more about how can reliable data de-risk strategic decisions for a VC, PE and Hedge funds.

🧬 European Life Sciences deals overview for 2023 & 2024 outlook 📈 https://lnkd.in/dsiQ5NpB Excited to share our latest publication. In this report, we delve into the dynamic landscape of life sciences investments across European targets, highlighting key trends across each deal type, notable deals, and emerging opportunities shaping the industry Explore the full report to stay informed and gain strategic perspectives on the future of life sciences investments in Europe #LifeSciences #Biotech #Investments

In Balentine's 2024 edition of its Capital Markets Forecast, we address Private Capital after the era of low rates and segments of the private markets that are attractive and deserve attention within: - Venture Capital - Real Estate - Opportunistic Credit - Senior Lending - Private Equity We also touch on why, though you can gain exposure to AI in public markets, the private markets (through venture) offer the most exciting opportunities. Investing in AI startups should be done in a diversified approach with established venture capital managers. Read more here, and sign up for additional insight into the capital markets.

𝐇𝐞𝐫𝐞’𝐬 𝐖𝐡𝐲 𝐋𝐚𝐬𝐭 𝐖𝐞𝐞𝐤’𝐬 𝐒𝐭𝐨𝐜𝐤 𝐌𝐚𝐫𝐤𝐞𝐭 𝐂𝐫𝐚𝐬𝐡 𝐈𝐬 𝐀 𝐖𝐚𝐫𝐧𝐢𝐧𝐠 𝐒𝐢𝐠𝐧 𝐅𝐨𝐫 𝐀𝐮𝐬𝐭𝐫𝐚𝐥𝐢𝐚’𝐬 𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐒𝐞𝐜𝐭𝐨𝐫 Investments in biotechnology are most impactful when made by those with deep pockets. Without funding from angel investors/venture capitalists, many biotech companies cannot continue to meaningfully function. Analysis of the recent downward spike in global markets may be an indicator that the Australian Biotech sector could be in trouble. Read More Here... https://lnkd.in/g-SgtmU5

Are you are a biotech looking to store, organize, visualize, and share your research data? Or perhaps a VC firm looking to recommend an easy to use, powerful, and low overhead solution to your investees, stop by the CDD Vault table and ask Michael Woodhouse, Juan Gijzelaar and I what we mean by Complexity Simplified!